Affordable Access

Multicenter phase II efficacy trial of toremifene in tamoxifen-refractory patients with advanced breast cancer.

Authors
Type
Published Article
Journal
Journal of Clinical Oncology
0732-183X
Publisher
American Society of Clinical Oncology
Publication Date
Volume
11
Issue
2
Pages
345–350
Identifiers
PMID: 8426212
Source
Medline

Abstract

We conclude that there is major cross-resistance between tamoxifen and toremifene and that only occasional tamoxifen-refractory patients will have objective responses to toremifene.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments
F